It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Zonula occludens-1 (ZO-1) is involved in the regulation of cell-cell junctions between endothelial cells (ECs). Here we identify the ZO-1 protein interactome and uncover ZO-1 interactions with RNA-binding proteins that are part of stress granules (SGs). Downregulation of ZO-1 increased SG formation in response to stress and protected ECs from cellular insults. The ZO-1 interactome uncovered an association between ZO-1 and Y-box binding protein 1 (YB-1), a constituent of SGs. Arsenite treatment of ECs decreased the interaction between ZO-1 and YB-1, and drove SG assembly. YB-1 expression is essential for SG formation and for the cytoprotective effects induced by ZO-1 downregulation. In the developing retinal vascular plexus of newborn mice, ECs at the front of growing vessels express less ZO-1 but display more YB-1-positive granules than ECs located in the vascular plexus. Endothelial-specific deletion of ZO-1 in mice at post-natal day 7 markedly increased the presence of YB-1-positive granules in ECs of retinal blood vessels, altered tip EC morphology and vascular patterning, resulting in aberrant endothelial proliferation, and arrest in the expansion of the retinal vasculature. Our findings suggest that, through its interaction with YB-1, ZO-1 controls SG formation and the response of ECs to stress during angiogenesis.
ZO-1, a cell junction protein, is essential for angiogenesis. Here the authors identify in endothelial cells unexpected associations of ZO-1 with stress granule proteins, such as YB-1, that are crucial for cytoprotection, implicating the ZO-1-YB-1 interaction in angiogenesis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Université de Montréal, Department of Pharmacology and Physiology, Faculty of Medicine, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2104 2136)
2 Université de Montréal, Department of Pharmacology and Physiology, Faculty of Medicine, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2104 2136); University of Toronto, Donnelly Centre, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
3 Centre Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Canada (GRID:grid.411418.9) (ISNI:0000 0001 2173 6322)
4 Institut de recherches cliniques de Montréal (IRCM), Montreal, Canada (GRID:grid.511547.3)
5 Institut de recherches cliniques de Montréal (IRCM), Montreal, Canada (GRID:grid.511547.3); Université de Montréal, Department of Biochemistry and Molecular Medicine, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2104 2136)
6 University of Toronto, Donnelly Centre, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
7 Centre Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Canada (GRID:grid.411418.9) (ISNI:0000 0001 2173 6322); Université de Montréal, Department of Pediatrics, Faculty of Medicine, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2104 2136)
8 McGill University, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada and Gerald Bronfman Department of Oncology, Faculty of Medicine, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
9 Université de Montréal, Department of Biochemistry and Molecular Medicine, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2104 2136); Université de Montréal, Maisonneuve-Rosemont Hospital Research Centre, Montréal, Quebec, Canada and Department of Medicine, Faculty of Medicine, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2104 2136)
10 Centre Hospitalier Universitaire Sainte-Justine Research Center, Montreal, Canada (GRID:grid.411418.9) (ISNI:0000 0001 2173 6322); Université de Montréal, Department of Pathology and Cell Biology, Faculty of Medicine, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2104 2136)
11 Université de Montréal, Department of Pharmacology and Physiology, Faculty of Medicine, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2104 2136); Université de Montréal, Centre d’Innovation Biomédicale (CIB), Faculty of Medicine, Montreal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2104 2136)